Drug intelligence / Profile preview

CT-P55

Development stage: Phase 3
Lead developer: Celltrion
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

CT-P55 is a biosimilar of secukinumab, developed by Celltrion. It is a monoclonal antibody that acts as an interleukin-17A (IL-17A) inhibitor. The drug is designed to closely replicate the efficacy and safety profile of the reference product, Cosentyx (secukinumab), which was originally developed by Novartis. Secukinumab and its biosimilars are used primarily for the treatment of autoimmune diseases such as moderate to severe plaque psoriasis, ankylosing spondylitis, and psoriatic arthritis. By inhibiting IL-17A, CT-P55 blocks pro-inflammatory pathways involved in these immune-mediated disorders[1][2][3][4][5].

Other names: secukinumab biosimilar

Targets

IL-17A (Interleukin-17A)

Beyond the preview

Go deeper on CT-P55.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CT-P55.

Explore the full profile